Journal Scans
Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
OS Benefit With Letrozole After 5-Year Tamoxifen
H Jin, D Tu, N Zhao, LE Shepherd, PE Goss
Yes
20110931
2011 Oct 31
J Clin Oncol
Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
J Clin Oncol. 2011 Oct 31;[Epub Ahead of Print], H Jin, D Tu, N Zhao, LE Shepherd, PE Goss
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study MA.17 was a phase III, double-blind, placebo-controlled trial designed to assess disease-free survival (DFS) in women with hormone receptor–positive early breast cancer who were treated with tamoxifen for 5 years and then given either letrozole (2.5 mg daily) or placebo. The study, which enrolled 5187 patients, was stopped early after the first interim analysis (40% of events occurred) showed that letrozole was associated...
